[HTML][HTML] Sunitinib resistance in renal cell carcinoma
C Morais - Journal of Kidney Cancer and VHL, 2014 - ncbi.nlm.nih.gov
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
[PDF][PDF] Sunitinib resistance in renal cell carcinoma
C Morais - core.ac.uk
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
Sunitinib resistance in renal cell carcinoma
M Christudas - Journal of Kidney Cancer and VHL, 2014 - search.proquest.com
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
Sunitinib resistance in renal cell carcinoma
C Morais - Journal of Kidney Cancer and VHL, 2014 - mail.jkcvhl.com
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
Sunitinib resistance in renal cell carcinoma
C Morais - Journal of Kidney Cancer and VHL, 2014 - cir.nii.ac.jp
抄録< jats: p> Of the many targeted therapies introduced since 2006, sunitinib has carved its
way to become the most commonly used first-line therapy for the treatment of metastatic …
way to become the most commonly used first-line therapy for the treatment of metastatic …
Sunitinib resistance in renal cell carcinoma
C Morais - Journal of Kidney Cancer and VHL, 2014 - jkcvhl.com
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
Sunitinib resistance in renal cell carcinoma
C Morais - Journal of kidney cancer and VHL, 2014 - pubmed.ncbi.nlm.nih.gov
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
Sunitinib resistance in renal cell carcinoma
C Morais - Journal of Kidney Cancer and VHL, 2014 - jkcvhl.com
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
[PDF][PDF] Sunitinib resistance in renal cell carcinoma
C Morais - pdfs.semanticscholar.org
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
Sunitinib resistance in renal cell carcinoma.
C Morais - Journal of Kidney Cancer and VHL, 2014 - europepmc.org
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …
become the most commonly used first-line therapy for the treatment of metastatic renal cell …